Art. -Nr.: HY-14603

Clioquinol

(Synonyms: Iodochlorohydroxyquinoline)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Clioquinol (Iodochlorhydroxyquin) is a topical antifungal agent with anticancer activity. Clioquinol acts as an oral antimicrobial agent for the research of diarrhea and skin infections. Antibiotic. Clioquinol is a chelator that binds to Zn²⁺ and Cu²⁺ with a greater affinity than it binds to Ca²⁺ and Mg²⁺. Clioquinol freely crosses the blood-brain barrier. Clioquinol can be used for the study of Alzheimer's disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.84%
CAS. Nr.: 130-26-7
Formel: C₉H₅ClINO
Molecular Weight:305.50

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Clioquinol Chemical Structure

CAS. Nr.: 130-26-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Clioquinol (Iodochlorhydroxyquin) is a topical antifungal agent with anticancer activity. Clioquinol acts as an oral antimicrobial agent for the research of diarrhea and skin infections. Antibiotic^[1]. Clioquinol is a chelator that binds to Zn²⁺ and Cu²⁺ with a greater affinity than it binds to Ca²⁺ and Mg²⁺. Clioquinol freely crosses the blood-brain barrier. Clioquinol can be used for the study of Alzheimer's disease^[2].

Alle Parasite Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	EC₅₀	>30 μM Compound: CQ	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay	[PMID: 26473791]
Caco-2	IC₅₀	19.29 μg/mL Compound: Cq	Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 37975824]
PBMC	CC₅₀	2 μM Compound: 2, Clioquinol	Cytotoxicity against PBMC Cytotoxicity against PBMC	[PMID: 17000109]
SH-SY5Y	EC₅₀	>1 μM Compound: Clioquinol	Neuroprotective activity against t-BuOOH-induced oxidative stress in human SH-SY5Y cells assessed as inhibition ROS accumulation pre-incubated for 24 hrs before t-BuOOH challnge for 30 mins by DCFH-DA probe based fluorescence assay Neuroprotective activity against t-BuOOH-induced oxidative stress in human SH-SY5Y cells assessed as inhibition ROS accumulation pre-incubated for 24 hrs before t-BuOOH challnge for 30 mins by DCFH-DA probe based fluorescence assay	[PMID: 29420891]

In Vitro

Clioquinol (0.01-1000 uM; 72 hours) shows anticancer activity against U251, and MV-4-11 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

The MV-4-11, and U-251 cell lines
Concentration:

0.01, 0.1, 1, 10, 100, 1000 uM
Incubation Time:

72 hours
Result:

The IC₅₀s were 32 and 46 μM in U251 and MV-4-11 cells, respectively.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 130-26-7
Appearance Solid
Molecular Weight 305.50
Formel C₉H₅ClINO
Color Light yellow to brown
SMILES

ClC1=C(C=CC=N2)C2=C(O)C(I)=C1
Synonyms

Iodochlorohydroxyquinoline
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All

Sort by:

Journal Impact Factor

J Transl Med

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]

2024 Dec 3;22(1):1095. PMID: 39623468
Oncogene

YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis. [Abstract]

2025 Dec 16. PMID: 41402633
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Int Immunopharmacol

Mitophagy-mtROS axis contributes to anti-tuberculosis-induced liver injury through activation of the cGAS-STING pathway in rat hepatocytes. [Abstract]

2025 May 30:160:114984. PMID: 40449272
Am J Respir Cell Mol Biol

Clioquinol Attenuates Pulmonary Fibrosis through Inactivation of Fibroblasts via Iron Chelation. [Abstract]

2021 Aug;65(2):189-200. PMID: 33861690
Front Mol Neurosci

The Role of Transient Receptor Potential A1 and G Protein-Coupled Receptor 39 in Zinc-Mediated Acute and Chronic Itch in Mice. [Abstract]

2022 Jan 12:14:768731. PMID: 35095413

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (163.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2733 mL

16.3666 mL

32.7332 mL

5 mM

0.6547 mL

3.2733 mL

6.5466 mL

10 mM

0.3273 mL

1.6367 mL

3.2733 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (6.81 mM); Suspended solution; Need ultrasonic and warming

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 2 mg/mL (6.55 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (423 KB)
- English - EN (423 KB)
- Français - FR (423 KB)
- Deutsch - DE (423 KB)
- Norwegian - NO (423 KB)
- Español - ES (423 KB)
- Swedish - SV (423 KB)
- Italian - IT (423 KB)
- Korean - KR (423 KB)
- Portuguese - PT (423 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Moe Wehbe, et al. Development of a copper-clioquinol formulation suitable for intravenous use. Drug Deliv Transl Res. 2018 Feb;8(1):239-251. [Content Brief]

[2]. Regland B, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):408-14. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2733 mL	16.3666 mL	32.7332 mL	81.8331 mL
	5 mM	0.6547 mL	3.2733 mL	6.5466 mL	16.3666 mL
	10 mM	0.3273 mL	1.6367 mL	3.2733 mL	8.1833 mL
	15 mM	0.2182 mL	1.0911 mL	2.1822 mL	5.4555 mL
	20 mM	0.1637 mL	0.8183 mL	1.6367 mL	4.0917 mL
	25 mM	0.1309 mL	0.6547 mL	1.3093 mL	3.2733 mL
	30 mM	0.1091 mL	0.5456 mL	1.0911 mL	2.7278 mL
	40 mM	0.0818 mL	0.4092 mL	0.8183 mL	2.0458 mL
	50 mM	0.0655 mL	0.3273 mL	0.6547 mL	1.6367 mL
	60 mM	0.0546 mL	0.2728 mL	0.5456 mL	1.3639 mL
	80 mM	0.0409 mL	0.2046 mL	0.4092 mL	1.0229 mL
	100 mM	0.0327 mL	0.1637 mL	0.3273 mL	0.8183 mL

Keywords

Clioquinol

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Clioquinol

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Alzheimer's Disease Compound Library

Antiparasitic Compound library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Cell Death Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Clioquinol

Alle Parasite Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Clioquinol Related Classifications

HY-14603 Related Classifications